ViaCell, a biotech firm developing cellular therapies for the treatment of cancer, genetic and cardiac diseases, and infertility, filed to go public once again. ViaCell had filed for an IPO in January 2002 but withdrew the offering on the last day of 2003. CS First Boston, UBS Investment Bank, Lazard and Leering Swann have been selected to underwrite the deal. Terms and timing have yet to be determined.
